A new breakthrough in the treatment of allogeneic γδ T cells, the potential for tumor treatment appears

On September 27th, the introduction of the progress of allogeneic γδ-T cell immunotherapy and the patient meeting held by Ji Dekang Democracy Office

September 27th, cum Dekang democracy do allogeneic γδ-T cells in the immune therapy of patients progress to introduce and will meet September 27, cum Dekang democracy do allogeneic γδ-T cells in the immune therapy of patients progress to introduce and will meet in September On the 27th, theintroduction of the progressof allogeneic γδ-T cell immunotherapy and the patient meeting forimmunization

Introduction: The therapeutic effect of allogeneic γδT cells allows us to see new hopes for overcoming cancer

Introduction: The effect of allogeneic γδT cell treatment allows us to see a new hope for conquering cancer.

At the introduction of allogeneic γδ-T cell immunotherapy and patient meeting held by Ji Dekang, the chief scientist of Ji De Kangmin, Professor Yin Zhinan, Dean of the Institute of Biomedical Translational Research of Jinan University, focused on the latest progress of his research team in the field of cell therapy

In fact, cell therapy has become one of the important development directions in China's future medical field

In fact, cell therapy has become one of the important development directions in China's future medical field

Development of immune cell therapy, source: Professor Yin Zhinan

 γδ-T cells are a subgroup of T cells whose TCR is composed of γ chain and δ chain, and are non-restricted cells of the major histocompatibility complex

T cell classification and its subgroups, Tan Siyi, etc.

T cell classification and its subgroups, Tan Siyi, etc.

Infected tumor immunity , domestic and foreign scholars represented by Professor Yin Zhinan have done a lot of research on its features and mechanisms, and found that γδT cells can perform complex functions, such as immune surveillance, immune regulation, and immune effects

The function and regulation mechanism of anti-tumor γδ T cells, source: Nature Reviews Cancer

Professor Yin Zhinan has been engaged in research in the field of γδ T cells for more than 20 years and discovered that γδ T cells provide an important protective effect against tumor immunity by providing early source IFN-γ

Schematic diagram of γδ T cell adoptive immunotherapy, Tan Siyi, et al.

Schematic diagram of γδ T cell adoptive immunotherapy, Tan Siyi, et al.

For the first time, the R&D team of Jidekangmin Biotechnology has proved the safety and effectiveness of allogeneic γδ-T cells from healthy people in the immunotherapy of advanced cancer through clinical studies

Over the years, the overall cancer mortality rate has hardly decreased, tumor treatment has not made great progress, and the median progression-free survival (PFS) has been extended, but overall survival (OS) has not been greatly improved

Comparison of γδ T cell therapy and CAR-T cell therapy

The team of Professor Yin Zhinan from the Institute of Biomedical Translational Research of Jinan University in China took the lead in completing the clinical research of allogeneic γδ T cells in the world from 2017 to 2018.

Proved safety and preliminary effectiveness for solid cancer

Allogeneic Vγ9Vδ2 T cells (“γδT cells” in human blood are mainly “Vγ9V δ2 T cells”) expanded with the new formula for the overall survival of patients with advanced liver cancer or lung cancer

132 patients with advanced tumors received ~414 cell reinfusion treatments (cells are from healthy people), Professor Yin Zhinan

As of September 2021, Jidekangmin's research team has followed up 8 patients with advanced liver cancer and 10 patients with advanced lung cancer (both receiving cell therapy 5 times or more), from their first infusion of allogeneic γδ-T Starting with cells, the current median survival time of these patients is 42.
4 months (range 30-50 months), and the overall survival rate is 5/18 (27.
78%)
.

Since their first infusion of allogeneic γδ-T cells, the median survival time of these patients is 42.
4 months (range 30-50 months), and the overall survival rate is 5/18 (27.
78%)
.
Since their first infusion of allogeneic γδ-T cells, the median survival time of these patients is 42.
4 months (range 30-50 months), and the overall survival rate is 5/18 (27.
78%)
.

Allogeneic γδ T cells have shown initial efficacy in the treatment of advanced liver cancer.
One of the patients with liver cancer had complete control of the metastatic lymph nodes.
Alnaggar, Mohammed et al.
“Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma .
" Journal for immunotherapy of cancer vol.
7,1 36.
8 Feb.
2019, doi:10.
1186/s40425-019-0501-8

Allogeneic γδ T cells have shown initial efficacy in the treatment of advanced liver cancer.
One of the patients with liver cancer had complete control of the metastatic lymph nodes.
Alnaggar, Mohammed et al.
“Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma .
" Journal for immunotherapy of cancer vol.
7,1 36.
8 Feb.
2019, doi:10.
1186/s40425-019-0501-8

This is the first time in the world to complete a 3-year follow-up for the treatment of advanced liver cancer and lung cancer with allogeneic γδ-T cells
.
Internationally, it was the first to prove the safety of allogeneic γδ T cell therapy in clinical use, demonstrated preliminary effectiveness for liver cancer and lung cancer, and significantly improved the quality of life and immune status of patients with advanced tumors, which will be important to the global cell therapy market Impact
.

This is the first time in the world to complete a 3-year follow-up for the treatment of advanced liver cancer and lung cancer with allogeneic γδ-T cells
.
This is the first time in the world to complete a 3-year follow-up for the treatment of advanced liver cancer and lung cancer with allogeneic γδ-T cells
.

Professor Yin Zhinan said that his team developed a patented γδ-T cell formula with fast expansion speed (10 days), high purity (>90%), long survival time (30 days), strong anti-apoptotic ability, and higher cancer Cell killing ability
.
As a special force in the treatment system, γδ T cells are expected to play a therapeutic role in the treatment of tumors, major refractory infectious diseases, and immune reconstruction, and play an irreplaceable and complementary role in immunotherapy
.

.
As a special force in the treatment system, γδ T cells are expected to play a therapeutic role in the treatment of tumors, major refractory infectious diseases, and immune reconstruction, and play an irreplaceable and complementary role in immunotherapy
.

.
As a special force in the treatment system, γδ T cells are expected to play a therapeutic role in the treatment of tumors, major refractory infectious diseases, and immune reconstruction, and play an irreplaceable and complementary role in immunotherapy
.

It should be pointed out that there are still some problems in the treatment of allogeneic γδ-T cells that need to be solved urgently
.
For example, the anti-tumor killing mechanism of γδ T cells, including molecular mechanisms and biophysical mechanisms, needs to be further studied; further improvement and research are needed to make γδ T cells have stronger killing ability and longer survival time.
Expansion conditions; exploring the efficacy of γδ T cells in combination with other immune cells, such as NK cells, on tumors; exploring and therapeutic antibodies, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic agents the effect of other anti-drug combination
.

It should be pointed out that there are still some problems in the treatment of allogeneic γδ-T cells that need to be solved urgently
.
It should be pointed out that there are still some problems in the treatment of allogeneic γδ-T cells that need to be solved urgently
.
Further in-depth research is needed, including molecular mechanisms and biophysical mechanisms; further improvements and research are needed to develop conditions for cultivating, activating, and expanding γδ T cells that have stronger killing ability and longer survival time; exploration is based on γδ T cells Combine with other immune cells, such as NK cells, for the efficacy of tumors; explore the efficacy of combined application with therapeutic antibodies, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic monoclonal antibodies
.
Further in-depth research is needed, including molecular mechanisms and biophysical mechanisms; further improvements and research are needed to develop conditions for cultivating, activation and expansion of γδ T cells with stronger killing ability and longer survival time; exploration is based on γδ T cells Combine with other immune cells, such as NK cells, for the efficacy of tumors; explore the efficacy of combined application with therapeutic antibodies, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic monoclonal antibodies
.

At the press conference, there were patients and clinical research participating institutions.
Professor Xu Kecheng, Dean of Fuda Cancer Hospital, also emphasized in his speech that the implementation of medical policies and supervision in the cell therapy industry needs to be strengthened.
The government encourages innovation and enterprises strengthen Innovation can enable patients to obtain more advanced therapies faster and benefit the general public
.

The implementation of medical policies and supervision of the cell therapy industry needs to be strengthened.
The government encourages innovation and enterprises strengthen innovation to allow patients to obtain more advanced therapies faster and benefit the general public
.
The implementation of medical policies and supervision of the cell therapy industry needs to be strengthened.
The government encourages innovation and enterprises strengthen innovation to allow patients to obtain more advanced therapies faster and benefit the general public
.

When asked about the availability of drugs, Professor Yin Zhinan said that the price can be reduced to 1/20~1/30 of the price of CAR-T cells .
Compared with the “sky price” of 1.
2 million, allogeneic γδ T cell therapy can be And there has been a very big improvement in this area, and there will be a downward price trend in the future
.

The price can be reduced to 1/20~1/30 of the price of CAR-T cells, which can be reduced to the price of CAR-T cells .
Compared with the “sky price” of 1.
2 million, the availability of allogeneic γδ T cell therapy is already very large.
The increase in the future will also be a price reduction trend
.
From 1/20 to 1/30, compared with the "sky price" of 1.
2 million, the accessibility of allogeneic γδ T cell therapy has been greatly improved, and the price will continue to decrease in the future
.

In short, allogeneic γδ-T cell therapy is expected to become a promising new method of tumor treatment
.

In short, allogeneic γδ-T cell therapy is expected to become a promising new method of tumor treatment
.
In short, allogeneic γδ-T cell therapy is expected to become a promising new method of tumor treatment
.

What is interesting is that the 9th International γδ T Cell Conference with Professor Yin Zhinan as the chairman of the conference will be held in Zhuhai, China on November 5-8, 2021
.

Assembly chaired by Professor Yinzhi Nan Ninth International , chaired by Professor Yinzhi Nan Assembly Ninth International T γδ cells γδ T cells meeting will be held in November 2021 held in Zhuhai, China 5-8
.
The conference will be held in Zhuhai, China on November 5-8, 2021
.

 

Note: Click on the link to register for free to participate in the 9th International γδ T Immune Cell Annual Conference
.
The link of the 9th International gd T Cell Conference: https://tcell2020.
medmeeting.
org/en or https://mm.
sciconf.
cn/en/minisite/index/5011 

Note: Click on the link to register for free to participate in the 9th International γδ T Immune Cell Annual Conference
.
Link of the 9th International gd T Cell Conference: https://tcell2020.
medmeeting.
org/en https://tcell2020.
medmeeting.
org/en https://tcell2020.
medmeeting.
org/en https://tcell2020.
medmeeting .
org / en or or https://mm.
sciconf.
cn/en/minisite/index/5011 https://mm.
sciconf.
cn/en/minisite/index/5011 https://mm.
sciconf.
cn/ en/minisite/index/5011  

 

Reference materials:

Reference materials:

1.
Tan Siyi, et al.
: New progress in anti-tumor clinical immunotherapy of human γδ T cells

1.
Tan Siyi, et al.
: New progress in anti-tumor clinical immunotherapy of human γδ T cells

2.
Xu, Yan et al.
“Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
” Cellular & molecular immunology vol.
18,2 (2021): 427- 439.
doi:10.
1038/s41423-020-0515-7

2.
Xu, Yan et al.
“Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
” Cellular & molecular immunology vol.
18,2 (2021): 427- 439.
doi:10.
1038/s41423-020-0515-7

3.
Xu, Yan et al.
“Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
” Cellular & molecular immunology vol.
18,2 (2021): 427- 439.
doi:10.
1038/s41423-020-0515-7

3.
Xu, Yan et al.
“Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
” Cellular & molecular immunology vol.
18,2 (2021): 427- 439.
doi:10.
1038/s41423-020-0515-7

4.
Professor Yin Zhinan's lecture: Global breakthrough tumor treatment new program new progress allogeneic Vγ9Vδ2-T cell immunotherapy

4.
Professor Yin Zhinan's lecture: Global breakthrough tumor treatment new program new progress allogeneic Vγ9Vδ2-T cell immunotherapy

 

Leave a message here